Platinum-Based Neoadjuvant Chemotherapy Before Radical Prostatectomy for Locally Advanced Prostate Cancer With Homologous Recombination Deficiency: A Case Report

More emerging evidence showed that homologous recombination (HR) defect (HRD) may predict sensitivity to platinum agents in metastatic prostate cancer (PCa). Platinum-based neoadjuvant chemotherapy for PCa with HRD has not been reported. Here, we reported a man diagnosed as locally advanced PCa with...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhuang, Junlong, Zhang, Shun, Qiu, Xuefeng, Fu, Yao, Ai, Shuyue, Zhao, Tingting, Yang, Yining, Guo, Hongqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8766302/
https://www.ncbi.nlm.nih.gov/pubmed/35070981
http://dx.doi.org/10.3389/fonc.2021.777318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8766302/
https://www.ncbi.nlm.nih.gov/pubmed/35070981
http://dx.doi.org/10.3389/fonc.2021.777318

Ejemplares similares